[The clinical and pathological characteristics and prognosis of pseudomyxoma peritonei]

Zhi-qiang Song1, Wen-ze Wang, Xing-hua Lu

  • 1Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China. szqinpumch@yahoo.com.cn

Zhonghua Nei Ke Za Zhi
|January 18, 2006
PubMed
Abstract

Insights

Pseudomyxoma peritonei (PMP) is a rare borderline malignancy. Diagnosis is often delayed, but pathological type and chemotherapy significantly impact prognosis, necessitating improved treatment strategies.

Area of Science:

  • Gastroenterology and Oncology
  • Pathology
  • Surgical Oncology

Context:

  • Pseudomyxoma peritonei (PMP) is a rare neoplastic condition characterized by mucinous ascites.
  • Delayed diagnosis is common, with many patients initially misdiagnosed.
  • The study retrospectively analyzed clinical and pathological data from 33 PMP patients.

Purpose:

  • To investigate the clinical and pathological characteristics of PMP.
  • To evaluate treatment modalities and patient prognosis.
  • To identify factors influencing survival in PMP patients.

Summary:

  • PMP presents with symptoms like bloating and abdominal distention, often with delayed diagnosis.
  • Diagnostic tools include tumor markers, imaging, and paracentesis, though the latter is often unsuccessful.
  • Debulking surgery combined with chemotherapy is the primary treatment, but lacks standardized protocols. Pathological type and chemotherapy influence survival.

Impact:

  • Highlights the diagnostic challenges and unique characteristics of PMP.
  • Underscores the need for improved treatment strategies for this rare condition.
  • Identifies pathological type and chemotherapy as key prognostic factors, guiding future research and clinical management.

Related Concept Videos